Analysts Set Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Price Target at $11.00

Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) have been given an average rating of "Buy" by the seven brokerages that are currently covering the company, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $11.00.

A number of research analysts recently issued reports on ACRS shares. Cantor Fitzgerald upgraded shares of Aclaris Therapeutics from a "neutral" rating to an "overweight" rating in a report on Wednesday, November 20th. HC Wainwright raised Aclaris Therapeutics from a "neutral" rating to a "buy" rating and set a $20.00 price target for the company in a research note on Monday, December 23rd. BTIG Research upgraded shares of Aclaris Therapeutics from a "neutral" rating to a "buy" rating and set a $8.00 price target for the company in a report on Tuesday, November 19th. StockNews.com upgraded shares of Aclaris Therapeutics from a "sell" rating to a "hold" rating in a research report on Friday, November 15th. Finally, Jefferies Financial Group raised shares of Aclaris Therapeutics from a "hold" rating to a "buy" rating and lifted their target price for the stock from $2.00 to $7.00 in a research note on Tuesday, November 19th.

Insider Buying and Selling at Aclaris Therapeutics

In other news, Director Anand Mehra bought 666,666 shares of Aclaris Therapeutics stock in a transaction dated Tuesday, November 19th. The stock was purchased at an average price of $2.25 per share, for a total transaction of $1,499,998.50. Following the purchase, the director now directly owns 710,030 shares in the company, valued at $1,597,567.50. The trade was a 1,537.37 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 6.40% of the company's stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the company. Point72 Asia Singapore Pte. Ltd. bought a new stake in Aclaris Therapeutics during the second quarter worth $119,000. Millennium Management LLC increased its position in shares of Aclaris Therapeutics by 1.9% during the 2nd quarter. Millennium Management LLC now owns 3,336,850 shares of the biotechnology company's stock valued at $3,671,000 after purchasing an additional 63,358 shares during the last quarter. Stonepine Capital Management LLC bought a new stake in shares of Aclaris Therapeutics during the 2nd quarter worth $2,120,000. Trium Capital LLP boosted its holdings in shares of Aclaris Therapeutics by 1.1% in the 3rd quarter. Trium Capital LLP now owns 1,912,990 shares of the biotechnology company's stock worth $2,200,000 after buying an additional 20,940 shares during the last quarter. Finally, Assenagon Asset Management S.A. bought a new position in Aclaris Therapeutics during the third quarter valued at about $214,000. 98.34% of the stock is owned by institutional investors.

Aclaris Therapeutics Stock Up 0.4 %

Shares of ACRS stock opened at $2.47 on Monday. The business has a fifty day simple moving average of $3.07 and a 200 day simple moving average of $1.89. The company has a market cap of $176.43 million, a P/E ratio of -4.75 and a beta of 0.54. Aclaris Therapeutics has a twelve month low of $0.86 and a twelve month high of $5.17.

Aclaris Therapeutics (NASDAQ:ACRS - Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.03). The company had revenue of $4.35 million for the quarter, compared to the consensus estimate of $8.31 million. Aclaris Therapeutics had a negative net margin of 136.65% and a negative return on equity of 40.26%. As a group, equities research analysts anticipate that Aclaris Therapeutics will post -0.75 earnings per share for the current fiscal year.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.